Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines
Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610
Recently, Shanghai Medicilon was awarded the title of “Excellent Expert Workstation” by the Shanghai Academician and Expert Workstation Guidance Office and the title of “2020
Shanghai Medicilon Inc.
Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China